HEAT Trial (HER2 Antibody Therapy with Lutetium-177) (RAD202)
NCT 06824155 Brief Summary This is a first-in-human, Phase 0/1, open-label study…
Read more arrow_forwardNCT 06824155 Brief Summary This is a first-in-human, Phase 0/1, open-label study…
Read more arrow_forwardNCT 01704716 Brief Summary This is a randomized study of the European…
Read more arrow_forwardACTRN 12625000191493 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardNCT 06349408 Brief Summary This is a Phase 1 multicenter, multi-regional, open-label,…
Read more arrow_forwardNCT 05774873 Brief Summary The primary objective of this study to evaluate…
Read more arrow_forwardNCT 05987332 Brief Summary This is a Phase 2/3, multi-arm, multi-stage, open-label…
Read more arrow_forwardNCT 05365659 Brief Summary This first-in-human study will evaluate the recommended dose…
Read more arrow_forwardNCT 06112314 Brief Summary This is a phase 3, randomized, controlled study…
Read more arrow_forwardACTRN 12619001768189 Brief Summary The aim of this clinical trial is to…
Read more arrow_forwardNCT 03959085 Brief Summary This phase III trial studies whether inotuzumab ozogamicin…
Read more arrow_forward